Komal Jhaveri

8.6k total citations · 3 hit papers
173 papers, 2.9k citations indexed

About

Komal Jhaveri is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Komal Jhaveri has authored 173 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 127 papers in Oncology, 124 papers in Pulmonary and Respiratory Medicine and 33 papers in Cancer Research. Recurrent topics in Komal Jhaveri's work include Advanced Breast Cancer Therapies (104 papers), HER2/EGFR in Cancer Research (75 papers) and Cancer Treatment and Pharmacology (71 papers). Komal Jhaveri is often cited by papers focused on Advanced Breast Cancer Therapies (104 papers), HER2/EGFR in Cancer Research (75 papers) and Cancer Treatment and Pharmacology (71 papers). Komal Jhaveri collaborates with scholars based in United States, Spain and United Kingdom. Komal Jhaveri's co-authors include Gary A. Ulaner, Shanu Modi, Aditya Bardia, Francisco J. Esteva, Christopher C. Riedl, Hope S. Rugo, Frederik Marmé, Sara M. Tolaney, Sarat Chandarlapaty and Florence Dalenc and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Komal Jhaveri

161 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

2023 210 citations Hope S. Rugo, Aditya Bardia et al. profile →
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

2022 176 citations Hope S. Rugo, Aditya Bardia et al. Journal of Clinical Oncology profile →
Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer

2025 16 citations Komal Jhaveri, Seock‐Ah Im et al. profile →

Peers

Countries citing papers authored by Komal Jhaveri

Since Specialization

Citations

This map shows the geographic impact of Komal Jhaveri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Komal Jhaveri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Komal Jhaveri more than expected).

Fields of papers citing papers by Komal Jhaveri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Komal Jhaveri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Komal Jhaveri. The network helps show where Komal Jhaveri may publish in the future.

Co-authorship network of co-authors of Komal Jhaveri

This figure shows the co-authorship network connecting the top 25 collaborators of Komal Jhaveri. A scholar is included among the top collaborators of Komal Jhaveri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Komal Jhaveri. Komal Jhaveri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer 2025 ·Clinical Cancer Research ·Timothy A. Yap, Jonathan W. Goldman, Shaveta Vinayak, Antoaneta Tomova, Erika Hamilton, Yoichi Naito, (unknown), Igor Bondarenko, Toshinari Yamashita, Li Zhou, (unknown), (unknown), (unknown), Feng Liu, Jennifer Park, Maria Delioukina, Komal Jhaveri	5
2	Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors 2025 ·Cancer Research Communications ·Funda Meric‐Bernstam, Martin Gutierrez, Enrique Sanz‐García, Diego Villa, Jun Zhang, Jennifer Friedmann, (unknown), Mark A. Socinski, John Sarantopoulos, Luis E. Raez, Quincy S. Chu, Maxime Chénard-Poirier, (unknown), Hong Ren, (unknown), Douglas A. Levine, Komal Jhaveri	1
3	489MO Patient-reported outcomes (PROs) with vepdegestrant (VEP) vs fulvestrant (FUL) in patients (pts) with estrogen receptor (ER) 1 gene mutated (ESR1m) ER+/human epidermal growth factor receptor 2 (HER2) : Advanced breast cancer (aBC) in the phase 3 VERITAC-2 trial 2025 ·Annals of Oncology ·(unknown), Michelino De Laurentiis, Xin Hu, Marina Elena Cazzaniga, C. Zamagni, Anne Patsouris, Sylvain Ladoire, A Rodríguez, Komal Jhaveri, Jiuwei Cui, Katarzyna J. Jerzak, Tetsuhiro Yoshinami, (unknown), Vincent Lambert, (unknown), David Chandiwana, Olga Valota, (unknown), E.P. Hamilton	1
4	7O Trastuzumab deruxtecan (T-DXd) ± pertuzumab (P) in previously untreated HER2+ metastatic breast cancer (mBC): Clinical efficacy and exploratory subgroup analyses in DESTINY-Breast07 2025 ·ESMO Open ·Fabrice André, Giulia Fabbri, R. McEwen, Tereza Vaclová, Sarah E. Boston, (unknown), (unknown), Sherene Loi, (unknown), (unknown), (unknown), (unknown), (unknown), Komal Jhaveri	3
5	Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2− Metastatic Breast Cancer 2025 ·Clinical Cancer Research ·Paula I. González-Ericsson, Nisha Unni, Komal Jhaveri, Erica Stringer-Reasor, Qi Liu, Yu Wang, Violeta Sánchez, (unknown), Melinda E. Sanders, Brian D. Lehmann, Justin M. Balko, Ben Ho Park, Brent N. Rexer, Ingrid A. Mayer, Carlos L. Arteaga	0
6	Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial 2024 ·Clinical Lung Cancer ·Jonathan W. Goldman, (unknown), Christophe Dooms, Komal Jhaveri, Maria J. de Miguel, Sarina A. Piha‐Paul, Nisha Unni, Aviad Zick, Amit Mahipal, Jennifer M. Suga, Charles Naltet, (unknown), John Crown, Judith D. Bebchuk, Lisa D. Eli, (unknown), Devalingam Mahalingam	1
7	First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses. 2024 ·Journal of Clinical Oncology ·Dejan Juric, Kevin Kalinsky, Nicholas C. Turner, Komal Jhaveri, Peter Schmid, Sherene Loi, Cristina Saura, Seock‐Ah Im, Patrapim Sunpaweravong, Huiping Li, Antonino Musolino, Qingyuan Zhang, Zbigniew Nowecki, Roland Leung, Eirini Thanopoulou, (unknown), Guiyuan Lei, Jacob Devine, Thomas J. Stout, Sibylle Loibl	23
8	Abstract PS17-01: Key drivers of therapeutic response and resistance to giredestrant from GO39932: a Phase Ia/b study in patients with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer 2024 ·Cancer Research ·Jackson J. Liang, Christy C. Ong, Jennifer M. Giltnane, Junko Aimi, Ching‐Wei Chang, Mary Gates, Jennifer Eng‐Wong, Pablo Ernesto Pérez, Komal Jhaveri, Elgene Lim, Nicholas C. Turner, Heather M. Moore	1
9	Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study. 2024 ·Journal of Clinical Oncology ·Sònia Pernas, Seock‐Ah Im, Masaya Hattori, Binghe Xu, Shusen Wang, Yen‐Shen Lu, Giuliano Borges, Junji Tsurutani, Komal Jhaveri, Qingyuan Zhang, Michelino De Laurentiis, Noelia Martínez-Jáñez, Erika Hamilton, Hope S. Rugo, Kevin Kalinsky, Sara M. Tolaney, Lei Shi, (unknown), (unknown), Aditya Bardia	1
10	Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2- metastatic breast cancer: A machine learning approach. 2024 ·Journal of Clinical Oncology ·Enrico Moiso, Emanuela Ferraro, Luc Cabel, Anton Safonov, (unknown), (unknown), Komal Jhaveri, Larry Norton, Mark E. Robson, Shanu Modi, Sarat Chandarlapaty, Pedram Razavi	1
11	196P Efficacy and safety of first-line (1L) ribociclib (RIB) + letrozole (LET) in patients (pts) with de novo metastatic disease and late recurrence from (neo)adjuvant therapy (tx) in MONALEESA (ML)-2 2023 ·ESMO Open ·Joyce O’Shaughnessy, (unknown), Stephen Chia, Claudine Isaacs, Michelino De Laurentiis, Sherko Küemmel, Komal Jhaveri, Wolfgang Janni, Hope S. Rugo, Agnes Lteif, (unknown), Howard Hu, Patrick Neven	0
12	383MO Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study 2023 ·Annals of Oncology ·Komal Jhaveri, (unknown), X. Cynthia, Elgene Lim, Kan Yonemori, Erika Hamilton, (unknown), S-A. Im, (unknown), Sarah Sammons, Manali Bhave, Peter A. Kaufman, C. Saura Manich, Tarek Meniawy, (unknown), Roohi Ismail‐Khan, Yuelin Li, Shawn T. Estrem, (unknown), M. Beeram	9
13	Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer? 2023 ·Cancer Treatment Reviews ·Chiara Corti, Carmine De Angelis, Giampaolo Bianchini, Luca Malorni, Mario Giuliano, Erika Hamilton, Rinath Jeselsohn, Komal Jhaveri, Giuseppe Curigliano, Carmen Criscitiello	36
14	Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer breakdown → 2022 ·Journal of Clinical Oncology ·Hope S. Rugo, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, P. Gómez Pardo, Komal Jhaveri, Rosemary Delaney, (unknown), Lanjia Lin, Wendy Verret, Sara M. Tolaney	176
15	The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer 2022 ·Breast Cancer Research and Treatment ·Aditya Bardia, Ingrid A. Mayer, Eric P. Winer, Hannah M. Linden, X. Cynthia, Barbara A. Parker, Meritxell Bellet, Carlos L. Arteaga, Sravanthi Cheeti, Mary Gates, Ching‐Wei Chang, Jill Fredrickson, Jill M. Spoerke, Heather M. Moore, Jennifer M. Giltnane, Lori S. Friedman, Edna Chow Maneval, Iris T. Chan, Komal Jhaveri	14
16	A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA -Mutated HER2-Positive Metastatic Breast Cancer 2021 ·Clinical Cancer Research ·Komal Jhaveri, Joshua Z. Drago, Payal D. Shah, Rui Wang, Fresia Pareja, (unknown), Alexia Iasonos, Sujata Patil, Neal Rosen, Monica Fornier, Nancy T. Sklarin, Sarat Chandarlapaty, Shanu Modi	26
17	Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted ⁸⁹Zr-Pertuzumab PET/CT 2020 ·Radiology ·Gary A. Ulaner, Jorge A. Carrasquillo, Christopher C. Riedl, Randy Yeh, Vaios Hatzoglou, Dara S. Ross, Komal Jhaveri, Sarat Chandarlapaty, David M. Hyman, Brian M. Zeglis, Serge K. Lyashchenko, Jason S. Lewis	45
18	A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer 2018 ·Clinical Cancer Research ·Erika Hamilton, Manish R. Patel, Anne Armstrong, Richard D. Baird, Komal Jhaveri, Matthias Hoch, Teresa Klinowska, Justin P.O. Lindemann, Shethah Morgan, Gaia Schiavon, Hazel M. Weir, Seock‐Ah Im	67
19	First-in-Human Human Epidermal Growth Factor Receptor 2–Targeted Imaging Using ⁸⁹Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer 2017 ·Journal of Nuclear Medicine ·Gary A. Ulaner, Serge K. Lyashchenko, Christopher C. Riedl, Shutian Ruan, Pat Zanzonico, Diana Lake, Komal Jhaveri, Brian M. Zeglis, Jason S. Lewis, Joseph A. O’Donoghue	141
20	HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development 2014 ·British Journal of Cancer ·Jasmeet Singh, Komal Jhaveri, Francisco J. Esteva	87

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact